Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
The mechanism behind behavioral side effects of popular weight loss drugs
Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been linked with behavioral side effects.
Weight-loss drugs linked to unexpected benefits and risks
The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks of addiction.
Study ties Ozempic-like drugs to dozens of benefits and risks
Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to increase the risk of many others.
Benefits and risks of popular weight-loss drugs revealed
Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes,
Mechanism Behind Weight Loss Drug Side Effects Unveiled
Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise
Weight-loss drugs reduce risk of Alzheimer’s, large study shows
Analysis of drugs such as Ozempic finds a lower health risk for 42 conditions but a higher rate of disorders such as arthritis
Study Shows Diabetes Drugs' Potential Beyond Weight Loss
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing them as miracle drugs.
Taking This Weight-Loss Medication Could Slash Dementia Risk, New Research Suggests
A new study found that GLP-1 medications like Ozempic can lower your risk for 42 conditions, including dementia. Here's what to know, per a neurologist.
Websites selling compounded GLP-1 RAs often misinform consumers, research reveals
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
News Medical on MSN4h
GLP1RA medications linked to behavioral side effects in type 2 diabetes and obesity
Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents-have been ...
Neuroscience News1d
GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks
A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...
Too Old to Operate3h
GLP1RA Use Increases Solid RGCs and Aborted Procedures in Endoscopy
The following is a summary of “Endoscopy and Anesthesia Outcomes Associated with Glucagon-Like Peptide-1 Receptor Agonist Use ...
EurekAlert!8h
What’s the mechanism behind behavioral side effects of popular weight loss drugs?
Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been ...